Company / Shareholders' Equity
FENNEC PHARMACEUTICALS INC. Shareholders' Equity History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$5.9M
FY2025
5-year range
-$11.6M / $29.1M
FY2021-FY2025
Trend
+49.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FENNEC PHARMACEUTICALS INC. reports negative total equity of -$6M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$6M in FY2025.
Declined from -$3M to -$6M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity increased 49.5% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.9M | +49.5% |
| FY2024 | -$11.6M | -352.4% |
| FY2023 | -$2.6M | -108.8% |
| FY2021 | $29.1M | +36.4% |
| FY2019 | $21.3M | -20.3% |
| FY2018 | $26.8M | +649.5% |
| FY2017 | $3.6M | +551.5% |
| FY2016 | $548.0K | -10.6% |
| FY2015 | $613.0K | +112.4% |
| FY2014 | -$5.0M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026